506
Participants
Start Date
September 30, 2005
Primary Completion Date
December 31, 2009
Study Completion Date
August 31, 2010
peginterferon plus ribavirin
peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
Department of Clinical and Experimental Medicine, Out-patients Hepatologic Unit, Azienda Ospedaliera di Padova., Padua
Regione Veneto
OTHER
University of Padova
OTHER
Azienda Ospedaliera di Padova
OTHER